R

Rocket Pharmaceuticals

D
RCKT
USD
-0.325
(-1.8492%)
Market Closed
16,889.00
Volume
-2.466
EPS
-
Div Yield
-6.227437
P/E
1,569,333,567.75
Market Cap
Today
-1.8492%
1 Week
3.541%
1 Month
2.862%
6 Months
-26.219%
12 Months
-15.607%
Year To Date
-42.327%
All Time
0%
News

Treasury Yields Decline as Market Anticipates Fed Rate Cuts

26.08.2024
Economy news

Novo Nordisk Surges in Profit and Sales

02.05.2024
Stocks news
More
Related Instruments
S
SPCE
-0.6
(-8.7273%)
USD
U
U
0.58
(2.6777%)
USD
M
MAXR
(%)
USD
A
ASTC
-0.29
(-4%)
USD
NOC
NOC
7.79
(1.5187%)
USD
LMT
LMT
4.94
(0.9031%)
USD
BA
BA
3.81
(2.589%)
USD
RTX
RTX
-1.53
(-1.258%)
USD
K
KTOS
-0.36
(-1.4821%)
USD
GD
GD
-2.49
(-0.807%)
USD

Title:
Rocket Pharmaceuticals

Sector:
Healthcare
Industry:
Biotechnology
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis.
Do you need help or have a question?
Contact Us